118 related articles for article (PubMed ID: 9633886)
21. Aprotinin and heparin monitoring during cardiopulmonary bypass.
Hunt BJ; Segal H; Yacoub M
Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
[TBL] [Abstract][Full Text] [Related]
22. Reheparinisation requirements after cardiopulmonary bypass in patients treated with aprotinin.
Bailey CR; Fisher AR; Wielogorski AK
Br Heart J; 1994 Nov; 72(5):442-5. PubMed ID: 7529520
[TBL] [Abstract][Full Text] [Related]
23. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
[TBL] [Abstract][Full Text] [Related]
24. Does heparin pretreatment affect the haemostatic system during and after cardiopulmonary bypass?
Brinks HJ; Weerwind PW; Bogdan S; Verbruggen H; Brouwer MH
Perfusion; 2001 Jan; 16(1):3-12. PubMed ID: 11192305
[TBL] [Abstract][Full Text] [Related]
25. Use of aprotinin during cardiopulmonary bypass in a patient with protein C deficiency.
Sievert A; McCall M; Blackwell M; Bradley S
J Extra Corpor Technol; 2003 Mar; 35(1):39-43. PubMed ID: 12680495
[TBL] [Abstract][Full Text] [Related]
26. Factor V(LEIDEN) and cardiopulmonary bypass: investigation of haemostatic parameters and the effect of aprotinin using an ex vivo model.
Linden MD; Schneider M; Erber WN
Perfusion; 2001 Nov; 16(6):476-84. PubMed ID: 11761087
[TBL] [Abstract][Full Text] [Related]
27. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations.
Dietrich W; Mössinger H; Spannagl M; Jochum M; Wendt P; Barankay A; Meisner H; Richter JA
J Thorac Cardiovasc Surg; 1993 Apr; 105(4):712-20. PubMed ID: 7682267
[TBL] [Abstract][Full Text] [Related]
28. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study.
Dietrich W; Dilthey G; Spannagl M; Jochum M; Braun SL; Richter JA
Anesthesiology; 1995 Oct; 83(4):679-89; discussion 29A-30A. PubMed ID: 7574046
[TBL] [Abstract][Full Text] [Related]
29. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
[TBL] [Abstract][Full Text] [Related]
30. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
[TBL] [Abstract][Full Text] [Related]
31. Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting.
Jansen PG; Baufreton C; Le Besnerais P; Loisance DY; Wildevuur CR
Ann Thorac Surg; 1996 May; 61(5):1363-6. PubMed ID: 8633942
[TBL] [Abstract][Full Text] [Related]
32. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
[TBL] [Abstract][Full Text] [Related]
33. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release.
Ashraf S; Tian Y; Cowan D; Nair U; Chatrath R; Saunders NR; Watterson KG; Martin PG
Ann Thorac Surg; 1997 Jan; 63(1):68-73. PubMed ID: 8993243
[TBL] [Abstract][Full Text] [Related]
34. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.
Despotis GJ; Filos KS; Levine V; Alsoufiev A; Spitznagel E
Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779
[TBL] [Abstract][Full Text] [Related]
35. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss.
Santamaría A; Mateo J; Oliver A; Litvan H; Murillo J; Souto JC; Fontcuberta J
Haematologica; 2000 Dec; 85(12):1277-84. PubMed ID: 11114135
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
37. A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopenia-associated antibodies in humans.
Heyligers JM; Lisman T; Verhagen HJ; Weeterings C; de Groot PG; Moll FL
J Vasc Surg; 2008 Feb; 47(2):324-9; discussion 329. PubMed ID: 18241756
[TBL] [Abstract][Full Text] [Related]
38. Low doses of aprotinin in aortocoronary bypass surgery--advantages and disadvantages.
Golański R; Golański J; Chizyński K; Iwaszkiewicz A; Zasłonka J; Pietrucha T; Chrul S; Watała C
Med Sci Monit; 2000; 6(4):722-8. PubMed ID: 11208399
[TBL] [Abstract][Full Text] [Related]
39. An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose.
Teligui L; Dalmayrac E; Mabilleau G; Macchi L; Godon A; Corbeau JJ; Denommé AS; Bouquet E; Boer C; Baufreton C
Interact Cardiovasc Thorac Surg; 2014 Jun; 18(6):763-9. PubMed ID: 24632424
[TBL] [Abstract][Full Text] [Related]
40. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG
Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
